StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) stock

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

Madrigal Pharmaceuticals enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Madrigal Pharmaceuticals's enterprise value was $9.50B on Nov 11, 2026, against $12.78B a year earlier. Over the last 5 years it ranged from $671.67M to $12.78B, with a median of $4.79B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$9.50B-23.7%
2025Dec 31, 2025$12.45B+113.0%
2024Dec 31, 2024$5.84B+40.4%
2023Dec 29, 2023$4.16B-14.4%
2022Dec 30, 2022$4.86B+330.2%
2021Dec 31, 2021$1.13B-18.4%
2020Dec 31, 2020$1.38B+45.3%
2019Dec 31, 2019$952.14M-23.6%
2018Dec 31, 2018$1.25B+9.9%
2017Dec 29, 2017$1.13B+591.5%
2016Dec 30, 2016$164.00M+318.4%
2015Dec 31, 2015$39.20M-76.4%
2014Dec 31, 2014$166.41M-38.2%
2013Dec 31, 2013$269.26M-36.6%
2012Dec 31, 2012$424.88M+153.6%
2011Dec 30, 2011$167.51M+33.1%
2010Dec 31, 2010$125.80M–

More Madrigal Pharmaceuticals figures

See a number that looks wrong?